We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Carrington Subsidiary DelSite and Nastech Sign Technology Evaluation Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Carrington Subsidiary DelSite and Nastech Sign Technology Evaluation Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Carrington Laboratories, Inc. has announced that its wholly-owned subsidiary, DelSite Biotechnologies, Inc., entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical Company Inc. for the purpose of evaluating DelSite's GelSite® polymer for enhancing intranasal delivery of peptide and protein therapeutics. Financial terms of the agreement were not disclosed.

The goal of the program is to assess whether the GelSite® polymer, in combination with Nastech's tight junction modulating technology, can increase bioavailability and provide additional pharmacokinetic profiles that could be useful for future development of Nastech's intranasally delivered peptides and proteins.

As part of the agreement, DelSite will conduct initial formulation development of the GelSite® polymer with Nastech formulations and will provide Nastech with final formulation characterization support.

GelSite® polymer is a novel, naturally occurring, mucoadhesive ionic carbohydrate polymer capable of forming a gel when brought into contact with nasal fluids. Gelling occurs with liquid as well as powder formulations and provides sustained release and prolonged nasal residence time that may enhance the nasal delivery of therapeutics or vaccines.

DelSite has evaluated GelSite® polymer for delivery of various protein/peptide therapeutics and vaccine antigens and has completed a series of toxicology studies on this polymer.

A Drug Master File (DMF) for use of GelSite® polymer in mucosal applications was filed in 2005 and was recently updated with both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA).

Carlton E. Turner, PhD, president and CEO of Carrington Laboratories and DelSite Biotechnologies, commented, "Nastech is a leader in the nasal delivery of therapeutic peptides and proteins in the pharmaceutical industry. GelSite® is a very versatile and unique polymer that has been successfully formulated for intranasal delivery of vaccines. GelSite's® unique properties, in combination with Nastech's cutting-edge tight junction modulating technologies, provide a potential opportunity to further expand nasal delivery of therapeutics."

DelSite's most advanced technology platform incorporating GelSite® polymer is a nasal powder vaccine delivery system (GelVac™) that has been developed and successfully tested in preclinical immunogenicity studies and in a Phase I clinical safety study (without an antigen).

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite® technology designed to provide controlled release of peptide and protein-based drugs.